ALSO NOTED: Spin-off may signal new era for Big Pharma R&D; Shire plots $394M Massachusetts plant;

> The Wall Street Journal notes the "dis-integration" of the traditional Big Pharma model following yesterday's announcement that AstraZeneca is spinning off its Swedish R&D facility for gastrointestinal therapies. Report

> U.K. drug maker Shire plans to build a new, $394 million manufacturing plant in Massachusetts and to add 680 jobs to its operations in the state over the next eight years. Report

> More U.S. adults are taking prescription drugs than ever, fueling $12 billion in additional spending during 2006. Report

> India's Cadila Healthcare got tentative FDA approval for its copycat version of carvedilol. Report

> Cadence Pharmaceuticals plans a private placement of 9.2 million shares of common stock in hopes of raising almost $50 million. Report

> Thailand will decide next week whether to negate compulsory licenses on four cancer drugs. Report

> Publicis, an advertising company whose pharma clients didn't get new drugs approved in 2007, missed its revenue-growth targets for the year. Report

> TorreyPines Therapeutics is taking a lashing from some of the analysts for its decision to cut staff as it restructures the company and focuses on its lead development programs. Report

> The House Committee on Energy and Commerce says it won't investigate a controversial FDA advisory committee vote on Dendreon's Provenge. Report

> Amgen CEO Kevin Sharer dropped by The Wall Street Journal to tout the company's chances in developing denosumab (D-mab) into a badly needed blockbuster. Report

And Finally... Soon, a urine test may be able to diagnose coronary artery disease. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Patients with epithelioid sarcoma previously had no targeted treatment options, but that'll change with Epizyme's approval for Tazverik.

With federal prosecutors laying waste to Insys' executive team, one big domino was still left to fall: Founder and former CEO John Kapoor.